Fitch Ratings recently released an analysis showing that Medicare’s drug price negotiation program is expected to deter investments into small molecule drugs.
Invest
Innovate
Cure
Incubate advocates for the patient, corporate, and investment communities by educating policymakers on the role of venture capital in bringing promising, innovative treatments to patients in need.
What We Do
-
Foster innovation
Help ensure a level global playing field for investment and promote policies that empower life science innovators to build and grow in the United States.
-
Safeguard advancements
Strengthen and protect U.S. intellectual property provisions by promoting patent and regulatory systems that encourage life sciences innovation.
-
Amplify the results
Spotlight the venture capital-driven breakthroughs that are transforming medicine for patients and health professionals around the globe.
Latest News
-
-
Medicare presses forward with drug price setting
In late August, the Centers for Medicare & Medicaid Services announced the first 10 drugs that will be subject to Medicare price setting under last year’s Inflation Reduction Act.
-
Mohit Manrao Talks Small-Molecule Penalty, Eliminating Cancer as a Cause of Death, and More
The small-molecule penalty “doesn’t create the right incentives for where we want to go with the Cancer Moonshot or driving cures,” Mohit reflected.
-
The Small Molecule Penalty: Explained by Incubate
making medicine
Stories from the Early-Stage Life Sciences Ecosystem
Listen to industry experts delve into the process behind scientific breakthroughs (and how many of them almost never happened), where the life science ecosystem is taking us next, and most importantly, what it means for patients.
Events
Global Health Idea Lab Virtual Summit
11.04.2022
Join our Virtual Summit as we embrace and nurture diverse talents, creativity, curiosity, and collaboration. We dive deep into the…